Palmetto GBA for California, Nevada and Hawaii, a regional Medicare carrier, has started covering posterior tibial nerve stimulation (PTNS) using Uroplasty's Urgent PC Neuromodulation System for the treatment of the symptoms of overactive bladder.
Uroplasty claims that Urgent PC Neuromodulation System is the only FDA-cleared system that delivers PTNS for the office-based treatment of overactive bladder and associated symptoms of urgency, frequency and urge incontinence.
Palmetto GBA will cover PTNS therapy for patients who have failed or demonstrated intolerance to standard anticholinergic drug therapy and the coverage includes an initial course of 12 weekly PTNS treatments, and for those patients who respond to the initial treatments, additional treatments once every three weeks for up to one year.
Uroplasty president and CEO David Kaysen said that they believe the strong clinical data that supports PTNS led the regional Medicare carriers to determine that PTNS treatments meet the criteria for medical necessity.
"We continue to present the growing body of clinical data to the medical directors of the other Medicare carriers, and private payers, to encourage them to cover and reimburse PTNS," Kaysen said.